PMID- 36612114
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 1
DP  - 2022 Dec 24
TI  - CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against 
      Cancer.
LID - 10.3390/cancers15010117 [doi]
LID - 117
AB  - Chimeric antigen receptor (CAR)-modified T cell therapy has been rapidly 
      developing in recent years, ultimately revolutionizing immunotherapeutic 
      strategies and providing significant anti-tumor potency, mainly in treating 
      hematological neoplasms. However, graft-versus-host disease (GVHD) and other 
      adverse effects, such as cytokine release syndromes (CRS) and neurotoxicity 
      associated with CAR-T cell infusion, have raised some concerns about the broad 
      application of this therapy. Natural killer (NK) cells have been identified as 
      promising alternative platforms for CAR-based therapies because of their unique 
      features, such as a lack of human leukocyte antigen (HLA)-matching restriction, 
      superior safety, and better anti-tumor activity when compared with CAR-T cells. 
      The lack of CRS, neurotoxicity, or GVHD, in the case of CAR-NK therapy, in 
      addition to the possibility of using allogeneic NK cells as a CAR platform for 
      "off-the-shelf" therapy, opens new windows for strategic opportunities. This 
      review underlines recent design achievements in CAR constructs and summarizes 
      preclinical studies' results regarding CAR-NK therapies' safety and anti-tumor 
      potency. Additionally, new approaches in CAR-NK technology are briefly described, 
      and currently registered clinical trials are listed.
FAU - Wlodarczyk, Marta
AU  - Wlodarczyk M
AUID- ORCID: 0000-0003-1545-2547
AD  - Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical 
      University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland.
AD  - Centre for Preclinical Research, Medical University of Warsaw, Banacha 1B, 02-097 
      Warsaw, Poland.
FAU - Pyrzynska, Beata
AU  - Pyrzynska B
AUID- ORCID: 0000-0002-0490-618X
AD  - Department of Biochemistry, Medical University of Warsaw, Banacha 1, 02-097 
      Warsaw, Poland.
LA  - eng
GR  - 2016/23/B/NZ5/02622/National Science Center/
PT  - Journal Article
PT  - Review
DEP - 20221224
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9817948
OTO - NOTNLM
OT  - CAR-NK
OT  - CAR-T
OT  - chimeric antigen receptors
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/09 06:00
MHDA- 2023/01/09 06:01
PMCR- 2022/12/24
CRDT- 2023/01/08 01:07
PHST- 2022/11/16 00:00 [received]
PHST- 2022/12/14 00:00 [revised]
PHST- 2022/12/20 00:00 [accepted]
PHST- 2023/01/08 01:07 [entrez]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/09 06:01 [medline]
PHST- 2022/12/24 00:00 [pmc-release]
AID - cancers15010117 [pii]
AID - cancers-15-00117 [pii]
AID - 10.3390/cancers15010117 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Dec 24;15(1):117. doi: 10.3390/cancers15010117.